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Here, we found that microRNA-24-1 (miR-24-1) is signiﬁcantly reduced in bladder cancer (BC)
tissues, suggesting that it functions as a tumour suppressor. Restoration of maturemiR-24-1 inhibits
cancer cell proliferation and induces apoptosis. Forkhead box protein M1 (FOXM1) is a direct target
gene ofmiR-24-1, as shown by genome-wide gene expression analysis and luciferase reporter assay.
Overexpressed FOXM1 is conﬁrmed in BC clinical specimens, and silencing of FOXM1 induces
apoptosis in cancer cell lines. Our data demonstrate that the miR-24-1–FOXM1 axis contributes to
cancer cell proliferation in BC, and elucidation of downstream signalling will provide new insights
into the molecular mechanisms of BC oncogenesis.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bladder cancer (BC) is the ﬁfth most common tumour in devel-
oped countries [1]. BCs are classiﬁed into ‘non-muscle-invasive
tumours’ and ‘muscle-invasive tumours’. The ﬁve-year survival
rate for patients with muscle-invasive tumours is about 60%, even
though that is close to 90% for patients with non-muscle-invasive
BC (NMIBC) [2]. Patients with NMIBC tend to have a high rate of
recurrence, and some cases become muscle invasive at recurrence
[3]. Recently, no effective chemotherapeutics have been found for
advanced BC by clinical trials [4,5]; therefore, it is desired that
novel prognostic markers and effective treatments based on RNA
network analyses.
The discovery of non-coding RNAs (ncRNAs) was an incredible
breakthrough in the post-genome era [6]. MicroRNAs (miRNAs)
are endogenous small ncRNAs (19–22 base pairs in length) repress-
ing protein-coding genes by binding their 3 prime untranslatedregion (UTR) [7]. Numerous studies have shown that miRNAs are
aberrantly expressed in various human malignancies and that they
have important roles in the initiation, development, and metastasis
of those malignancies [8–11]. Moreover, normal regulations can be
destroyed by tumour-suppressive or oncogenic miRNAs in malig-
nancies [12]. Therefore, detection of aberrantly expressed miRNAs
is an important ﬁrst step to elucidate miRNA-mediated oncogenic
pathways.
Recently, miRNA expression studies of human malignancies
revealed that microRNA-24-1 (miR-24-1) was aberrantly expressed
in several types of cancer tissues [13–19]. However, the
functional role of miR-24-1 in BC is unclear. The purpose of this
study was to investigate the functional signiﬁcance of miR-24-1
and to identify the target genes regulated by the miRNA in BC.
We found that restoration of mature miR-24-1 inhibited cancer
cell proliferation. In silico database analysis showed that
forkhead box protein M1 (FOXM1) was a potential target gene
of miR-24-1. FOXM1 has been reported to modulate drug
sensitivity and resistance in various tumour types [20]. Elucidat-
ing the cancer pathways and targets regulated by the tumour-
suppressive miR-24-1–FOXM1 axis will extend new insights of
BC oncogenesis.
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2.1. Clinical specimens and cell culture
The tissue specimens for quantitative real-time reverse tran-
scription polymerase chain reaction (RT-PCR) were collected from
patients with BC (n = 46) who had received cystectomy or
transurethral resection of bladder tumour (TUR-BT) at Kagoshima
University Hospital between 2003 and 2013. Normal bladder
epithelia (n = 16) were derived from patients with non-cancerous
disease. The specimens were staged according to the American
Joint Committee on Cancer-Union Internationale Contre le Cancer
tumour-node-metastasis (TNM) classiﬁcation and histologically
graded [21]. Our study was approved by the Bioethics Committee
of Kagoshima University; written prior informed consent and
approval were obtained from all patients. The patients’ back-
grounds and clinicopathological characteristics are summarised
in Table 1.
We used two human BC cell lines: BOY, which was established
in Kagoshima University [22] from an Asian male patient (age
66 years) diagnosed with stage III BC with lung metastasis; and
T24, an invasive BC cell line obtained from the American Type
Culture Collection. Both cell lines were maintained in minimum
essential medium (MEM) supplemented with 10% fetal bovine
serum in a humidiﬁed atmosphere containing 5% CO2 and 95% air
at 37 C.
2.2. Tissue collection and RNA extraction
Tissues were immersed in RNAlater (Ambion, Austin, TX, USA)
and stored at 20 C until RNA extraction. Total RNA, including
miRNA, was extracted using the mirVana™ miRNA isolation kit
(Ambion) following the manufacturer’s protocol.
2.3. Quantitative real-time RT-PCR (qRT-PCR)
TaqMan probes and primers for FOXM1 (P/N: Hs01073586_m1;
Applied Biosystems, Foster City, CA, USA) were assay-on-demand
gene expression products. We followed the manufacturer’s proto-
col for PCR conditions. Stem-loop RT-PCR (TaqMan MicroRNA
Assays; P/N: 000402 for miR-24-1; Applied Biosystems) was used
to quantify miRNAs according to previously published conditionsTable 1
Characteristic of patients.
Bladder cancer (BC)
Total number 46
Median age (range), years 70.5 (47–91)
Gender
Male 37
Female 9
Stage
pTa 4
pT1 10
pT2 14
pT3 6
pT4 3
Unknown 9
Grade
Low 14
High 29
Unknown 3
Operation
TUR-BT 30
Total cystectomy 16
Normal bladder epithelium (NBE)
Total number 16[23]. To normalise the data for quantiﬁcation of FOXM1 mRNA
and the miRNA, we used human GUSB (P/N: Hs99999908_m1;
Applied Biosystems) and RNU48 (P/N: 001006; Applied Biosys-
tems), respectively, and the DDCt method was employed to calcu-
late the fold change.
2.4. Transfection with mature miRNA and small interfering RNA
(siRNA)
As described elsewhere [24], the BC cell lines were transfected
with Lipofectamine RNAiMAX transfection reagent (Invitrogen,
Carlsbad, CA, USA) and Opti-MEM (Invitrogen) with 10 nM mature
miRNA. Pre-miR and negative-control miRNA (Applied Biosystems)
were used in gain-of-function experiments, whereas FOXM1 siRNA
(cat No. HSS103713; Invitrogen) and negative-control siRNA
(D-001810-10; Thermo Fisher Scientiﬁc, Waltham, MA, USA) were
used in loss-of-function experiments. Cells were seeded in six-well
plates for protein extraction (2  105 cells per well) and apoptosis
(1  105 cells per well), in 24-well plates for well), and in 96-well
plates for XTT assays (3  103 cells per well).
2.5. Cell proliferation assays
Cell proliferation was determined using XTT assays performed
according to the manufacturer’s instructions (Roche Applied
Sciences, Tokyo, Japan), as described previously [25].
2.6. Flow cytometry
BC cell lines were transiently transfected with transfection
reagent only (mock), miR-control, miR-24-1, si-control, or si-
FOXM1 in 6-well tissue culture plates, as described earlier [25].
Cells were harvested by trypsinization 72 h after transfection and
washed in cold phosphate-buffered saline (PBS). For apoptosis
assay, double staining with FITC-Annexin V and propidium iodide
(PI) was carried out using a FITC Annexin V Apoptosis Detection
Kit (BD Biosciences, Bedford, MA, USA) according to the manufac-
turer’s recommendations and immediately analysed within 1 h
by ﬂow cytometry (CyAn ADP analyzer; Beckman Coulter, Brea,
CA, USA). Cells were sorted into viable cells, dead cells, early apop-
totic cells, and apoptotic cells using Summit 4.3 software (Beckman
Coulter), and the percentages of early apoptotic and apoptotic cells
from each experiment were then compared.
Cells for the cell cycle analysis were stained with PI using the
Cycletest™ PLUS DNA Reagent Kit (BD Biosciences) following the
protocol and analysed by CyAn ADP analyzer. The percentages of
the cells in the G1, S and G2/M phase were counted and compared.
Experiments were performed in triplicate.
2.7. Western blot analysis
Cells were harvested 72 h after transfection, and lysates were
prepared. Thirty micrograms of protein were separated by NuPAGE
on 4–12% bis–tris gels (Invitrogen) and transferred to PVDF mem-
branes. Immunoblotting was carried out with diluted (1:1000)
anti-FOXM1 antibodies (#5436; Cell Signaling, Danvers, MA,
USA), anti-PARP antibodies (#9542; Cell Signaling), anti-Cleaved
PARP antibodies (#5625; Cell Signaling) and anti-GAPDH antibod-
ies (MAB374; Chemicon, Temecula, CA, USA). Speciﬁc complexes
were visualised with an echochemiluminescence (ECL) detection
system (GE Healthcare, Little Chalfont, UK).
2.8. Plasmid construction and dual-luciferase reporter assays
Partial wild-type sequences of the FOXM1 30 untranslated region
(UTR) or those with a deleted miR-24-1 target site (positions
P < 0.0001
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Fig. 1. Expression levels ofmiR-24-1 in BC clinical specimens and cell lines and effects of restoringmiR-24-1 on cell proliferation. (A)miR-24-1 expression levels in BC clinical
specimens (BC and normal bladder epithelia) and BC cell lines (BOY and T24) were measured by qRT-PCR. Data were normalized to the expression of the RNU48 gene. (B) Cell
proliferation was determined by XTT assay 72 h after transfection with 10 nM miR-24-1. ⁄P < 0.05.
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Fig. 2. Effects of miR-24-1 transfection on apoptosis in BC cell lines. Ratio of the apoptotic cell fractions (early apoptotic + apoptotic cells) in miR-24-1 transfectants in
comparison with mock and miR-control transfectants. Data for the apoptotic cell fractions were expressed as the relative value of the average expression of the mock
transfectant.
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Fig. 3. Western blot analysis for apoptotic markers in BC cell lines. Protein
expression of cleaved PARP and PARP was evaluated by Western blotting 72 h after
transfection with miR-24-1. GAPDH was used as a loading control.
S. Inoguchi et al. / FEBS Letters 588 (2014) 3170–3179 3173908–914 of the FOXM1 30UTR) were inserted between the XhoI and
PmeI restriction sites in the 30UTR of the hRluc gene in the psi-
CHECK-2 vector (C8021; Promega, Madison, WI, USA). The synthes-
ised DNA was cloned into the psiCHECK-2 vector. T24 cells were
transfected with 15 ng of the vector and 10 nM miR-24-1 using
Lipofectamine 2000 (Invitrogen). The activities of ﬁreﬂy and renilla
luciferases in cell lysates were determined with a dual-luciferase
assay system (E1960; Promega). Normalised data were calculated
as the ratio of renilla/ﬁreﬂy luciferase activities.
2.9. Statistical analysis
Relationships between 2 or 3 variables and numerical values
were analysed using the Mann–Whitney U test or Bonferroni-
adjusted Mann–Whitney U test. Expert StatView software, version
4, was used in these analyses.
3. Results
3.1. miR-24-1 expression in BC specimens
The expression level of miR-24-1 was evaluated in normal blad-
der epithelia (n = 16) and BC tissues (n = 46). miR-24-1 expressionCe
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Fig. 4. Effects of miR-24-1 transfection on cell cycle in BC cell lines. Upper: the bar chart
typical results of cell cycle analysis of mock, miR-control, or miR-24-1 transfectants.was signiﬁcantly lower in tumours than in non-cancerous tissues
(P < 0.0001; Fig. 1A). We could not ﬁnd signiﬁcant relationship
between any of the clinicopathological parameters (i.e., tumour
stage or grade) and miR-24-1 expression (data not shown). In BC
cell lines (BOY and T24) also exhibited low expression of miR-
24-1 compared to normal bladder epithelia (Fig. 1A).G1
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(BOY and T24)
In order to investigatemiR-24-1 function, gain-of-function stud-
ies were performed by using BOY and T24 cell lines transfected
with the miRNA. XTT assays demonstrated that signiﬁcant inhibi-
tion of cell proliferation was found in miR-24-1 transfectants in
comparison with mock or miR-control transfectants (Fig. 1B).
3.3. Effects of miR-24-1 transfection on apoptosis and cell cycle in BC
cell lines
Because miR-24-1 transfection inhibited cell proliferation in BC
cell lines, we hypothesised that miR-24-1 induction may induce
apoptosis and/or cell cycle arrest. Hence, we performed ﬂow
cytometry and analysed the numbers of apoptotic cells following
restoration of miR-24-1 expression. The apoptotic cell fractions
(apoptotic and early apoptotic cells) were signiﬁcantly larger in
miR-24-1 transfectants than in mock or miR-control transfectants
(Fig. 2, upper panel). Fig. 2 (lower panel) representatively showed
that the apoptotic and early apoptotic fractions (upper right and
lower right in the quadrant images) were larger in miR-24-1 trans-
fectants than in mock transfectants or the control. The induction of
apoptosis by miR-24-1 was conﬁrmed by Western blotting. As
shown in Fig. 3, the protein expression levels of Cleaved PARPTable 2
Forty-two highly expressed genes putatively regulated by miR-24-1 in clinical BC specime
Entrez Gene ID Gene symbol Expression Fold change Desc
2305 FOXM1 up 94.05 Fork
4751 NEK2 up 71.54 NIM
9928 KIF14 up 48.65 Kine
1116 CHI3L1 up 46.52 Chiti
6362 CCL18 up 42.41 Chem
23397 NCAPH up 32.80 Non-
55355 HJURP up 31.25 Holli
54972 TMEM132A up 27.55 Tran
2069 EREG up 26.91 Epire
993 CDC25A up 22.25 Cell
6374 CXCL5 up 20.63 Chem
7849 PAX8 up 19.55 Paire
55784 MCTP2 up 19.17 Mult
30820 KCNIP1 up 16.71 kV c
4320 MMP11 up 16.40 Matr
51514 DTL up 16.22 Dent
990 CDC6 up 15.25 Cell
57863 CADM3 up 15.06 Cell
9982 FGFBP1 up 14.67 Fibro
140766 ADAMTS14 up 13.29 ADA
56937 PMEPA1 up 13.08 Pros
343035 RD3 up 12.79 Retin
23293 SMG6 up 12.75 Smg
5676 PSG7 up 12.67 Preg
43 ACHE up 12.25 Acet
3589 IL11 up 12.09 Inter
90381 C15orf42 up 11.98 Chro
4680 CEACAM6 up 11.85 Carc
157570 ESCO2 up 11.31 Estab
388228 SBK1 up 10.71 SH3-
1824 DSC2 up 10.63 Desm
55771 PRR11 up 10.62 Proli
6664 SOX11 up 10.56 SRY
4319 MMP10 up 10.56 Matr
113730 KLHDC7B up 10.51 Kelch
2538 G6PC up 10.45 Gluc
55723 ASF1B up 10.43 Anti-
3832 KIF11 up 10.39 Kine
85285 KRTAP4-1 up 10.28 Kera
8061 FOSL1 up 10.26 FOS-
51397 COMMD10 up 10.25 COM
113235 SLC46A1 up 10.12 Soluwas signiﬁcantly increased in miR-24-1 transfectants compared
with the counter parts. In terms of the cell cycle distribution, num-
ber of cells in the G2/M phase was signiﬁcantly larger in miR-24-1
transfectants than in mock or miR-control transfectants (Fig. 4).
3.4. Identiﬁcation of candidate miR-24-1 target genes in BC cells
To identify genes targeted bymiR-24-1, in silico analysis was
performed by using the TargetScan program. We found 4321 genes
having putative target sites formiR-24-1 in their 30UTRs. We exam-
ined gene expression signatures in Gene Expression Omnibus
(GEO) database to evaluate upregulated genes in BC specimens.
Among the 4321 genes, 2061 genes were signiﬁcantly upregulated
in 90 BCs compared to 6 normal bladder epithelia (accession num-
bers, GSE11783 and GSE31684). Among them, 42 genes were
markedly upregulated (fold change >10) and were considered as
promising candidate oncogenes regulated by miR-24-1 in BC
(Table 2). We spotlighted the FOXM1 gene because it was the top
in the list.
3.5. Direct regulation of FOXM1 by miR-24-1
Next, qRT-PCR and Western blot analysis were performed to
conﬁrm that restoration of miR-24-1 resulted in FOXM1 downreg-
ulation in BOY and T24 cells. The expression levels of FOXM1ns (fold change >10).
ription P-value
head box M1 4.38E-05
A-related kinase 2 4.38E-05
sin family member 14 4.38E-05
nase 3-like 1 (cartilage glycoprotein-39) 2.49E-04
okine (C-C motif) ligand 18 7.80E-05
SMC condensin I complex, subunit H 4.98E-05
day junction recognition protein 4.38E-05
smembrane protein 132A 4.38E-05
gulin 1.28E-04
division cycle 25A 4.38E-05
okine (C-X-C motif) ligand5 5.67E-05
d box 8 4.67E-05
iple C2 domains, transmembrane 2 5.67E-05
hannel interacting protein 1 7.32E-05
ix metallopeptidase 11 (stromelysin 3) 4.38E-05
icleless E3 ubiquitin protein ligase homolog (Drosophila) 4.38E-05
division cycle 6 4.38E-05
adhesion molecule 3 4.98E-05
blast growth factor binding protein1 4.38E-05
M metallopeptidase with thrombospondin type 1 motif, 14 2.09E-04
tate transmembrane protein, androgen induced 1 2.35E-04
al degeneration 3 7.80E-05
-6 homolog, nonsense mediated mRNA decay factor (C. elegans) 4.67E-05
nancy speciﬁc beta-1-glycoprotein 7 (gene/pseudogene) 6.87E-05
ylcholinesterase 6.87E-05
leukin 11 2.65E-04
mosome 10 open reading frame, human C15orf42 1.54E-04
inoembryonic antigen-related cell adhesion molecule 6 3.15E-04
lishment of sister chromatid cohesion N-acetyltransferase 2 1.21E-04
binding domain kinase 1 2.47E-03
ocollin2 4.99E-04
ne rich 11 4.38E-05
(sex determining region Y)-box 11 2.35E-04
ix metallopeptidase 10 (stromelysin 2) 3.54E-04
domain containing 7B 8.31E-05
ose-6-phosphatase, catalytic subunit 6.05E-05
silencing function 1B histone chaperone 4.38E-05
sin family member 11 4.38E-05
tin associated protein 4-1 2.21E-04
like antigen 1 1.45E-04
M domain containing 10 7.32E-05
te carrier family 46 (folate transporter), member 1 4.38E-05
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Fig. 6. Silencing of FOXM1mRNA and protein expression by si-FOXM1 transfection in BC cells and effects of silencing FOXM1 on cell proliferation. (A) FOXM1mRNA expression
was measured 72 h after transfection with si-FOXM1. GUSB was used as an internal control. (B) FOXM1 protein expression was measured by Western blotting 72 h after
transfection with si-FOXM1. GAPDH was used as a loading control. (C) Cell proliferation was measured by the XTT assay. ⁄P < 0.05.
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Fig. 8. Western blot analysis of apoptotic markers in BC cell lines. Protein
expression of cleaved PARP and PARP was evaluated by Western blotting 72 h
after transfection with si-FOXM1. GAPDH was used as a loading control.
3176 S. Inoguchi et al. / FEBS Letters 588 (2014) 3170–3179mRNA and protein were signiﬁcantly suppressed inmiR-24-
1 transfectants compared to mock or miR-control transfectants
(P < 0.005, Fig. 5A and B).
We then carried out luciferase reporter assays in T24 cells in
order to ﬁnd out whether FOXM1 was directly regulated by miR-
24-1. The TargetScan database predicted that there is one binding
site formiR-24-1 in the 30UTR of FOXM1 (positions 908–914,
Fig. 5C). We employed vectors encoding wild-type sequence of
the 30UTR of FOXM1mRNA in partial where the predictedmiR-24-
1 target sites were located. We found that the luminescence inten-
sity was signiﬁcantly reduced by cotransfection withmiR-24-1 and
the vector carrying the wild-type 30UTR of FOXM1, whereas
transfection with the deletion vector (positions 908–914 had been
removed) blocked the decrease in luminescence (P = 0.001, Fig. 5C).
These data suggested that miR-24-1 bound directly to speciﬁc site
in the 30UTR of FOXM1 mRNA.
3.6. Effects of FOXM1 knockdown on cell proliferation and apoptosis in
BC cell lines
To investigate the functional role of FOXM1, loss-of-function
studies were carried out by using si-FOXM1 transfectants. First,
the knockdown efﬁciency of si-FOXM1 transfection was evaluatedin BOY and T24 cells. Western blotting and qRT-PCR showed that
si-FOXM1 effectively downregulated FOXM1 expression in BOY
and T24 cells (Fig. 6A and B). XTT assays showed that cell prolifer-
ation was inhibited in si-FOXM1 transfectants compared to mock
or si-control transfectants in BOY and T24 cells (Fig. 6C).
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Fig. 9. mRNA expression of FOXM1 in BC clinical specimens and cell lines and association of FOXM1 expression with clinicopathological parameters. (A) FOXM1 mRNA
expression levels in BC clinical specimen (BC and normal bladder epithelia) and BC cell lines (BOY and T24) were determined by qRT-PCR. GUSB was used as an internal
control. (B) FOXM1 expression was signiﬁcantly higher in patients with invasive BC compared to patients with superﬁcial BC. FOXM1 expression was signiﬁcantly higher in
patients with high-grade BC than in patients with low-grade BC.
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the ratio of apoptotic cell number in si-FOXM1 transfectants was
larger than those in mock and si-control transfectants 72 h after
transfection (Fig. 7, upper panel). As shown in the representative
quadrant images in Fig. 7 (lower panel), the apoptotic and early
apoptotic fractions were greater in si-FOXM1 transfectants than
in mock transfectants or si-control. Therefore, transient transfec-
tion with si-FOXM1 induced apoptosis in BC cell lines. To conﬁrm
the induction of apoptosis by si-FOXM1, We performed Western
blotting. The protein expression levels of Cleaved PARP was
signiﬁcantly increased in si-FOXM1 transfectants in comparison
with mock or si-control transfectants (Fig. 8).
3.7. Expression of FOXM1 in BC clinical specimens
qRT-PCR analysis showed that FOXM1 mRNA expression levels
were signiﬁcantly higher in 46 clinical BC specimens than in 16
non-BC specimens (P < 0.0001, Fig. 9A). To determine whether
the levels of FOXM1 mRNA in tumour tissues correlated with clin-
icopathological factors, we analysed FOXM1 expression levels in
human tumour samples. FOXM1 expression increased from the
superﬁcial to invasive stage (P = 0.0093, Fig. 9B). FOXM1 expression
also increased from low-grade to high-grade tumours (P = 0.0128,
Fig. 9B). These results suggested that FOXM1 was signiﬁcantly
upregulated in BC and may be a putative oncogene in BC.
4. Discussion
Aberrant expression of miRNAs disrupts the tightly regulated
RNA networks in cancer cells, and failure of these networks causes
cancer development and metastasis [12]. Therefore, strategies to
identify differentially expressed miRNAs and miRNA-regulated
cancer pathways are being developed as a new direction in cancer
research in the post-genome sequencing era. Therefore, in previous
works, we have reported that tumour-suppressive miRNAs
mediate novel molecular targets and pathways in several types
of cancers [26–29]. In this study, we focused on miR-24-1 becausethe functional role of miR-24-1 was controversial in the past
miRNA studies [13–19]. In the current study, miR-24-1 was signif-
icantly downregulated in BC tissues compared with normal blad-
der epithelia. Our data showed that restoration of miR-24-1
signiﬁcantly inhibited cancer cell proliferation and induced
apoptosis as well as cell cycle G2 arrest, suggesting its tumour-
suppressive function in BC cells. The tumour-suppressive role of
miR-24-1 has been reported in previous studies of other cancer
types, such as colorectal cancer, laryngeal squamous cell
carcinoma, and prostate cancer [13–15].
Contrary to these reports, overexpression of miR-24-1 has been
observed in several types of cancers and has been shown to func-
tion as an oncogene [16–19]. In glioma cells, upregulation of
miR-24-1 is a common event; moreover, downregulation of miR-
24-1 inhibited glioma cell proliferation both in vitro and in vivo
[30]. These data are contradictory to our present data in BC. It is
difﬁcult to explain the differences in the tumour-suppressive and
oncogenic functions of miR-24-1 in different cancer types. Elucida-
tion of the molecular mechanisms of aberrantmiR-24-1 expression
in each cancer type is necessary. miR-24-1 might regulates differ-
ent molecular targets and networks in different cancers, which
may explain our contradictory results.
miRNAs have unique ability to regulate multiple protein-coding
genes. Bioinformatic predictions suggest that miRNAs regulate 30–
60% of the protein-coding genes in human [8]. Reduced expression
of tumour-suppressive miRNAs may cause overexpression of onco-
genes in cancer cells. To better understand BC oncogenesis, we
identiﬁed miR-24-1 target genes using in silico analysis. Recent
miRNA studies in our laboratory have utilised this strategy to iden-
tify novel molecular targets and pathways regulated by tumour-
suppressive miRNAs in several cancers, including BC [26–29].
In this study, we identiﬁed FOXM1 as a target of tumour-
suppressive miR-24-1 and validated the direct binding of this
miRNA to the 30UTR using luciferase reporter assays. FOXM1 is a
member of the FOX family of transcription factors, and overexpres-
sion of FOXM1 has been reported in many types of human cancers
[31]. Our present data showed FOXM1 was upregulated in BC
Table 3
Signiﬁcantly enriched annotations (downstream genes of FOXM1), P < 1.0E-03.
Number
of genes
Annotations KEGG entry
number
P-value Genes
16 Focal adhesion 4510 2.16.E-09 MET, ACTN1, ITGA6, PDGFC, ITGA3, CCND1, FLNA, SPP1, CAPN2, CAV1, ARHGAP5, AKT1,
CAV3, PIK3CD, BCL2, PPP1CC
9 Arrhythmogenic right ventricular
cardiomyopathy (ARVC)
5412 2.12.E-07 ACTN1, ITGA6, ITGA3, SLC8A1, TCF7, DMD, LMNA, DAG1, GJA1
13 Endocytosis 4144 6.11.E-07 MET, ADRB2, F2R, TGFBR2, DNM2, EHD1, CAV1, EHD4, CAV3, RAB31, ARRB1, LDLR, AP2A1
7 Colorectal cancer 5210 8.83.E-06 BIRC5, TGFBR2, CCND1, TCF7, AKT1, PIK3CD, BCL2
8 Apoptosis 4210 8.70.E-06 PRKAR2B, FAS, CAPN2, IRAK1, IL1RAP, AKT1, PIK3CD, BCL2
11 Chemokine signaling pathway 4062 1.54.E-05 PREX1, CXCL2, CXCL3, GNB4, CXCL1, ADCY3, PLCB3, AKT1, PIK3CD, RASGRP2, ARRB1
14 Pathways in cancer 5200 3.85.E-05 MET, ITGA6, BIRC5, TGFBR2, ITGA3, CCND1, FAS, TCF7, AKT1, WNT5B, WNT10B, PIK3CD,
BCL2, PPARG
7 ECM-receptor interaction 4512 6.51.E-05 SDC1, SDC4, ITGA6, ITGA3, SPP1, CD44, DAG1
7 Dilated cardiomyopathy 5414 9.41.E-05 ITGA6, ITGA3, SLC8A1, ADCY3, DMD, LMNA, DAG1
7 Gap junction 4540 8.76.E-05 PDGFC, TUBB2B, TUBB2A, ADCY3, PLCB3, TUBB6, GJA1
7 Chagas disease (American
trypanosomiasis)
5142 2.21.E-04 TGFBR2, FAS, SERPINE1, IRAK1, PLCB3, AKT1, PIK3CD
5 Endocrine and other factor-
regulated calcium reabsorption
4961 2.85.E-04 DNM2, SLC8A1, PLCB3, ATP1B3, AP2A1
5 Pathogenic Escherichia coli infection 5130 4.51.E-04 TUBB2B, TUBB2A, KRT18, TUBB6, ARHGEF2
5 Inositol phosphate metabolism 562 5.80.E-04 PI4KA, IMPA2, PLCB3, PIK3CD, PLCD3
5 Acute myeloid leukemia 5221 5.80.E-04 CCND1, TCF7, AKT1, PIK3CD, PIM1
6 Salivary secretion 4970 5.35.E-04 ADRB2, ATP2B4, KCNN4, ADCY3, PLCB3, ATP1B3
6 Small cell lung cancer 5222 5.02.E-04 ITGA6, ITGA3, CCND1, AKT1, PIK3CD, BCL2
6 Prostate cancer 5215 6.43.E-04 PDGFC, CCND1, TCF7, AKT1, PIK3CD, BCL2
6 Hypertrophic cardiomyopathy (HCM) 5410 4.41.E-04 ITGA6, ITGA3, SLC8A1, DMD, LMNA, DAG1
Table 4
Upregulated genes involved in the annotations on Table 3.
Entrez Gene ID Gene symbol Expression Fold change Description P-value
6696 SPP1 up 35.94 Secreted phosphoprotein 1 0.00105
5054 SERPINE1 up 23.16 Serpin peptidase inhibitor, clade E 0.00105
332 BIRC5 up 17.27 Baculoviral IAP repeat containing 5 0.00105
2919 CXCL1 up 12.82 Chemokine (C–X–C motif) ligand 1 0.00105
2921 CXCL3 up 12.26 Chemokine (C–X–C motif) ligand 3 0.00111
2920 CXCL2 up 7.83 Chemokine (C–X–C motif) ligand 2 0.00174
5331 PLCB3 up 3.46 Phospholipase C, beta 3 0.00105
5292 PIM1 up 3.22 Pim-1 oncogene 0.00195
3675 ITGA3 up 3.04 Integrin, alpha 3 0.01138
595 CCND1 up 2.53 Cyclin D1 0.01227
3654 IRAK1 up 2.40 Interleukin-1 receptor-associated kinase 1 0.00111
3949 LDLR up 2.23 Low density lipoprotein receptor 0.01660
160 AP2A1 up 2.00 Adaptor-related protein complex 2, alpha 1 subunit 0.04582
207 AKT1 up 1.88 v-Akt murine thymoma viral oncogene homolog 1 0.00132
6385 SDC4 up 1.76 Syndecan 4 0.00908
10938 EHD1 up 1.56 EH-domain containing 1 0.00752
9181 ARHGEF2 up 1.46 Rho/Rac guanine nucleotide exchange factor (GEF) 2 0.00840
4000 LMNA up 1.38 Lamin A/C 0.02865
1605 DAG1 up 1.32 Dystroglycan 1 (dystrophin-associated glycoprotein 1) 0.04294
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of a member of genes that are critical for cell cycle progression,
such as Aurora B, Cyclin B1, and CDC25B [32]. Interestingly, FOXM1
also stimulates the expression of SKP2 and CKS1, which are
involved in the proteolysis of p27kip1 and in G1/S progression
[33]. Our previous study of urothelial carcinoma showed that
SKP2 and CKS1 expression correlated with tumour stage, grade,
and progression [34]. Overexpression of FOXM1 has been reported
in many types of human cancers [35], and our present data in BC
conﬁrmed the results of these previous studies. Therefore, down-
regulation of miR-24-1 in BC cells causes overexpression the
FOXM1-SKP2/CSK1 axis and promotes aggressive cancer behaviour
via regulation of p27kip1 degradation.
Furthermore, we investigated the molecular mechanisms
downstream of miR-24-1–FOXM1 signalling using si-FOXM1 trans-
fectants (Table 3). Our results showed that SPP1, SERPINE1, BIRC5,
and CXCLs were potential targets of miR-24-1–FOXM1 signalling
in BC cells (Table 4). Among these, our recent study showed that
the tumour-suppressive miR-195/497 cluster directly regulatedBIRC5 in BC cells [28]. BIRC5 is an inhibitor of apoptosis (IAP) and
is preferentially expressed in many malignancies, including BC
[36]. Several studies have shown that BIRC5 is directly regulated
by FOXM1 [37,38], indicating that the miR-24-1–FOXM1-BIRC5 axis
contributes substantially to BC oncogenesis.5. Conclusions
miR-24-1 was frequently downregulated in clinical BC speci-
mens and appeared to function as a tumour suppressor through
regulating the oncogenic FOXM1 transcription factor. Elucidating
cancer pathways mediated through the tumour-suppressive
miR-24-1–FOXM1 axis should provide novel insights into oncogenic
mechanisms in BC and new therapeutics for BC treatment.Disclosure statement
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